Dr. Yang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
8700 Beverly Blvd
Ste 8211
Los Angeles, CA 90048Phone+1 310-423-5841Fax+1 310-423-0387- Is this information wrong?
Education & Training
- Icahn School of Medicine at Mount SinaiFellowship, Adult Cardiothoracic Anesthesiology, 2010 - 2011
- Icahn School of Medicine at Mount SinaiFellowship, Critical Care Medicine, 2009 - 2010
- Johns Hopkins UniversityResidency, Anesthesiology, 2005 - 2009
- Flushing Hospital Medical CenterResidency, Internal Medicine, 2002 - 2005
- West China University of Medical SciencesClass of 1994
Certifications & Licensure
- CA State Medical License 2011 - 2025
- NY State Medical License 2010 - 2025
- American Board of Anesthesiology Anesthesiology
Publications & Presentations
PubMed
- 2 citationsOvert Disseminated Intravascular Coagulation with Severe Hypofibrinogenemia During Veno-Venous Extracorporeal Membrane Oxygenation.Stephen Yang, Brittney Williams, David Kaczorowski, Michael Mazzeffi> ;The Journal of Extra-Corporeal Technology. 2022 Jun 1
- 1 citationsThrombopoietin, Soluble CD40 Ligand, and Platelet Count During Veno-arterial Extracorporeal Membrane Oxygenation.Michael A. Mazzeffi, Reney Henderson, Elizabeth K. Powell, Erik Strauss, Brittney Williams, Kenichi A. Tanaka, Stephen Yang, Kristopher B. Deatrick, Ronson J. Madathil> ;ASAIO Journal. 2021 Jun 2
- Precise control of maxillary multidirectional movement in Le Fort I osteotomy using a surgical guiding device.Xue, C.,Xu, H.,Tian, Y.,Yang, X.,Luo, E.,Bai, D.> ;Br J Oral Maxillofac Surg. 2018 Sep 11
- Join now to see all
Press Mentions
- Apexigen Reports Third Quarter 2022 Financial Results and Provides Business UpdateNovember 15th, 2022
- Apexigen Announces Nature Medicine Publication and ASCO Presentation on the Phase 2 PRINCE Trial Showcasing Distinct Biosignatures in Metastatic Pancreatic Cancer Patients Treated with Sotigalimab and/or Nivolumab in Combination with ChemotherapyJune 6th, 2022
- Apexigen to Host Key Opinion Leader Webinar on Sotigalimab in Post-Anti-PD-(L)1 MelanomaNovember 9th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: